Upload
truongdan
View
221
Download
0
Embed Size (px)
Citation preview
Preliminary Results Year Ended December 2011
John Dawson – Chief Executive Richard Wright – Finance Director
March 2012
2
2011 Highlights Three acquisitions completed with annualised revenue of £4.7m
Good growth in promoted products
Hydromol (25%) Oncology (10%)
Total sales down £3.9m against Deltacortril fall of £8.8m Total sales £46.0m (2010: £49.9m) Deltacortril sales £4.7m (2010: £13.5m)
PBT £10.7m (2010 £12.9m) Excluding Deltacortril £7.5m (2010: £5.4m)
Strong free cash flow of £8.4m
Strong balance sheet with gearing at 1.4 times EBITDA
Full year dividend increased by 32% to 0.75p (2010: 0.57p )
4 4
Background to Alliance
Started in 1998 as a speciality pharma company
Profitable, cash generative, dividend paying with low gearing
Proven business model focusing on acquisition of mature niche medicines with limited competition
Reinforced by selective promotional activity to deliver organic growth
Virtual model, with manufacturing, storage, logistics and sales forces outsourced
Sales mainly in UK, but also into 20+ other countries
Strong track record of 21 acquisitions in 14 years building up a portfolio of over 50 products
5
Niche brands that have stood the test of time
Product Life-cycle
Development Biotechs • development risk +++
In-patent • high price/short life • big Pharma • heavy marketing • volume risk ++
Higher volume – generics • very price competitive • price risk ++ Lower volumes – no generics
Launch Patent Expiry
- limited or no competition - 10+ years out of patent - stable sales - low risk
Time Cash
6 6
Longevity of niche prescription brands
Product 2011 Sales Launched By Launch
Date Alliance Since Description
Nu-Seals £5.3m Lilly 1978 2002 Low dose aspirin for prevention of heart attacks and strokes
Deltacortril £4.7m Pfizer 1957 2006 Steroid to control immune system in a variety of conditions
Forceval £4.2m Unigreg 1970 2004 Complete supplement of micro-nutrients
ImmuCyst £4.1m Cambridge Labs 2001 2010 Immunotherapy for non muscle invasive bladder cancer
Hydromol £3.6m Quinoderm 1987 2006 Range of emollient products used in the management of eczema and other dry skin conditions
Syntocinon/ Syntometrine £2.4m Sandoz 1956 1998/
2006 Childbirth: assist labour/prevent haemorrhage after delivery
Xenazine / Nitoman £2.3m Roche 1971 2010 Treatment for the alleviation of a wide range of hyperkinetic
movement disorders (e.g. chorea in Huntington’s disease)
Buccastem £2.1m Reckitt & Colman 1987 2009 Buccal tablet for treatment of nausea and vomiting
Toxicology product £1.5m Berk
Pharmaceuticals 1991 2010 Toxicology product sold into Government stockpile on a 2½ year cycle
Vitamin E £1.4m Roche 1989 2010 Only licensed liquid formulation treatment for correction of Vitamin E deficiency available in the UK
Average age 33 years
7 7
Sustainability of sales from non-promoted products
Like for like sales of non-promoted products*,indexed to 100 at January 2003
0
50
100
150
200
Jan-0
3Ju
l-03
Jan-0
4Ju
l-04
Jan-0
5Ju
l-05
Jan-0
6Ju
l-06
Jan-0
7Ju
l-07
Jan-0
8Ju
l-08
Jan-0
9Ju
l-09
Jan-1
0Ju
l-10
Jan-1
1Ju
l-11
Inde
xed
to 1
00 a
t Jan
03
Demonstrates sustainability of sales over 9 year period
3.5% average annual growth rate
*Excludes Deltacortril
8
Deltacortril: a special case Commercial management in a multi-source market
*Illustrative
0
2
4
6
8
10
12
14
16
2007 2008 2009 2010 2011 2012*
£m
Deltacortril sales
9
Risk reduction through diversity – over 50 products
Hydromol7.5%Oncology
10.4%
Nu-Seals11.1%
Deltacortril9.8%
Forceval8.8%
Other (40+ products)
32.3%
Toxicology Product3.1%
Vitamin E3.0%
Xenazine4.7%
Buccastem4.4%
Syntocinon / Syntometrine
5.1%
Pro forma 2011 revenue segmentation
Shaded = promoted
10
Selective promotion when economically justified
ImmuCyst • Immunotherapy for non-
muscle-invasive bladder cancer
• Promoted using bespoke contract field force
• Sales currently £4.1m pa Gelclair • Biofilm product for oral
mucositis associated with cancer therapies
• Sales currently £0.9m
Hydromol • Range of emollients for
remission of eczema • Acquired from Ferndale Labs
in 2006 • Using bespoke contract field
force covering hospital and general practice
• Grown from £0.9m to £3.6m and still growing
12
2011 results – summary
Sales £46.0m (2010: £49.9m)
Operating profit* £12.3m (2010: £18.7m)
Pre-tax profit* £10.7m (2010: £16.4m)
Adjusted basic EPS 3.62p (2010: 5.07p)
Free cash flow £8.4m (2010: £12.3m)
Net bank debt £18.4m (2010: £17.0m), with gearing at 1.4 times EBITDA
Final dividend proposed up 25% to 0.50p
Total dividend up 32% to 0.75p
*Before exceptional items
13 13
2011 Sales movements
2011 £m
2010 £m
Change £m
Hydromol Growth of 25% 3.6 2.9 +0.7
Oncology LFL growth of 10% plus full year of sales 5.0 3.9 +1.1
Nu-Seals Market share gain offset by price decrease 5.3 4.8 +0.5
Toxicology product Lowest point of 2.5 year replacement cycle 1.5 3.2 (1.7)
Other Cambridge Labs Full year effect 6.8 4.6 +2.2
2011 Acquisitions Annualised sales of £4.7m 1.6 - +1.6
Deltacortril Additional competition and reduction in market size
4.7 13.5 (8.8)
Other 3% growth from core non-promoted brands 17.5 17.0 +0.5
Total 46.0 49.9 (3.9)
Sales history
14
-
10.0
20.0
30.0
40.0
50.0
60.0
Sal
es £
m
Underlying Deltacortril* 10 months annualised ** excluding Deltacortril
Five year compound annual growth rate to 2011:
9% organic (5%**)
13% acquisitions
22% combined (19%**)
Profit history
-
2
4
6
8
10
12
14
16
18
04/05 2005* 2006 2007 2008 2009 2010 2011
Ann
ual /
Ann
ualis
ed p
re-ta
x pr
ofit
befo
re
exce
ptio
nal i
tem
s £m
Underlying Deltacortril * 10 months annualised
15
16
Income Statement £’m 2011 2010
Sales 46.0 49.9
Gross profit 24.5 30.4
Gross margin % 53.3% 60.9%
Operating costs (11.4) (10.9)
Amortisation (0.7) (0.8)
Operating profit (pre-exceptionals) 12.3 18.7
Operating profit % 26.8% 37.5%
Financing costs (1.6) (2.3)
Adjusted PBT (pre-exceptionals) 10.7 16.4
Exceptional items - (3.5)
Reported PBT 10.7 12.9
Tax (2.1) (3.9)
Profit After Tax 8.6 9.0
Basic EPS 3.63p 3.96p
Adjusted EPS 3.63p 5.07p
Corporation tax
£000 2011 2010
PBT 10,712 12,872
Tax charge 2,076 3,918
Effective rate in income statement 19.4% 30.4%
Remove prior year adjustments 225 (215)
Remove impact of reduction in UK tax rate on deferred tax liability
314 141
Underlying tax charge 2,615 3,844
Underlying effective rate in income statement 24.4% 29.9%
Cash tax payable in respect of 2011 2,046
Effective cash tax rate 19.1%
17
18
Cash Flow
£’m 2011 2010
Operating profit 12.3 18.7 Depreciation and amortisation 1.0 1.0 Working capital (1.8) (1.8) Cash flow from trading 11.5 17.9 Interest (1.5) (2.0) Refinancing - (1.5) Capital expenditure (0.1) (0.9) Tax paid (1.5) (1.3) Free cash flow 8.4 12.2 Acquisitions (8.6) (14.3) Equity issued 0.2 7.5 Dividend (1.4) (0.7) Underlying debt (increase)/decrease (1.4) 4.7
19
Balance Sheet
£’m Dec 11 Dec 10 Change Intangibles: Product licences 66.1 60.3 +5.8
Inventories 5.7 4.5 +1.2
Trade and other receivables 8.7 9.7 (1.0)
Trade and other payables (8.4) (11.9) +3.5
Taxes (current and deferred) (5.1) (4.5) (0.4)
Other net assets - (0.1) (0.1)
Net cash 1.1 2.0 (0.9)
Bank loans (19.5) (19.0) (0.5)
Net bank debt (18.4) (17.0) (1.4) Convertible loan stock (4.5) (4.9) +0.4 Equity 44.1 36.1 +8.0
21
Growth outlook - trading
Hydromol 2011 sales of £3.6m
25% growth rate
Oncology 2011 sales of £5.0m
10% growth rate (LFL)
looking for further products to add to portfolio
Forceval China good medium term growth potential
Non-promoted products provide modest growth
Toxicology product 2012/13 tender won
Latest acquisitions showing promise
Buccastem nausea and vomiting
Anbesol mouth pain
Ashton & Parsons Infant Powders teething and colic
Rizuderm severe acne
Quinoderm moderate acne
22 22
Acquisitions in 2011
Anbesol and Ashton & Parsons from Reckitt Benckiser for £2.6m in April Anbesol
Relief of mouth pain, sales £1.3m pa Ashton & Parsons Infant Powders
Teething pain and associated colic, sales £0.8m pa, production issues to resolve
Six products from Beacon Pharmaceuticals for £2.4m in September Total sales of £2m, gross margin £0.9m Main product is Rizuderm (isotretinoin), for treatment of severe acne
Quinoderm and Ceanel from Ferndale for £1.5m in December Combined sales of around £0.6m Quinoderm is an OTC acne treatment and Ceanel is a shampoo treatment for scalp psoriasis
£13.5m of bank facility available to fund further acquisitions
23 23
Acquisitions – track record
16 Brands Fostering
Arrangement
Nu-Seals £9.0m
Symmetrel & Slow K
£4.0m
Distamine £0.5m
Alphaderm Aquadrate
£2.1m
Forceval £7.0m
Periostat £1.8m
4 Derma Brands £0.9m
Dermamist £0.26m
Hydromol £3.3m
4 Brands
£2.1m
C A R A D E R M
1998
2001
Atarax
Deltacortril Terracortrill
£1.0m
Forceval China
£1.95m
Permitabs £0.8m
Syntometrine
£2.0m
Pavacol D £0.6m
• 21 deals in 14 years
• Every year since 2006
Buccastem Timodine
£7.5m
Cambridge £14.3-16.4m
Anbesol Ashton &
Parsons £2.6m
1999
2002
2004
2006
2007
2008
2009
2010
2011
Rizuderm + 5 Products
£2.4m
Quinoderm Ceanel £1.5m
24 24
Summary
Robust business model Strong underlying growth
Stability of finance Growing size of portfolio diversifies risk Good capacity for future acquisitions – actively evaluating opportunities
26 26
Top 20 Investors: 5 March 2012 Holder / Fund Manager No. of Shares % Holding
Director & Related 67,635,893 28.13%
Nigel Wray 33,871,995 14.11%
Aviva Investors Global Services 23,716,755 9.88%
MVM Life Science Partners 19,300,000 8.03%
Slater Investments 9,145,000 3.81%
Artemis Fund Managers 7,948,549 3.31%
LGT Capital Management 7,196,071 3.00%
Investec Asset Management 6,750,000 2.81%
Hargreave Hale 6,180,750 2.57%
Brown Shipley Asset Management 5,996,624 2.50%
BlackRock Investment Management (UK) Limited 5,321,500 2.22%
Henderson Global Investors 4,200,450 1.75%
Barclays Wealth 3,982,232 1.66%
Cavendish Asset Management 2,944,000 1.23%
Seymour Pierce 2,699,119 1.12%
Hargreaves Lansdown Asset Management 2,276,044 0.95%
TD Direct Investing 2,244,471 0.93%
Redmayne Bentley Stockbrokers 2,004,489 0.84%
NCL Smith & Williamson Investments 1,914,000 0.80%
Adam & Co 1,562,720 0.65%
Total No of Share Owners - 845 No of Shares in Issue – 240,067,284
27 27
Convertible Unsecured Loan Stock
£4.4m of CULS remaining, paying 8% coupon Was £7.5m, but £3.1m converted since March 2010
Convertible at the option of the holders at any time up to 30 November 2013 at 21 pence per share
20.9m additional shares if all £4.4m convert
Otherwise redeemed at par
Publicly traded with a current price c. £1.40*
Held mainly by a small number of income funds
*As at 14 March 2012
28 28
Board members
Richard Wright, Finance Director: MA, Chartered Accountant, >20 years experience across various industries, joined 2007
Michael Gatenby, Non Executive Chairman MA. FCA ex-director of Hill Samuel and Co, ex-Vice Chairman of Charterhouse Bank. Holds a number of non executive directorships
John Dawson, CEO Pharmacist, MSc Finance; > 40yrs sector experience, founder of Alliance
Andrew Smith, Non Executive Director Senior positions held at SmithKline Beecham Pharmaceuticals, Diversified Health Systems Europe, Cerebrus plc and Parexel International
Thomas Casdagli, Non Executive Director Partner in MVM Life Science Partners, Chartered Accountant, graduated from Oxford in Molecular and Cellular Biochemistry, joined March 2009
Paul Ranson, Non Executive Director LL.B Barrister Solicitor. >25 years sector experience
Peter Butterfield, Director – UK Ex- UK Commercial Manager of Cambridge Laboratories Ltd, graduated from University of Edinburgh with BSc (Hons) specialising in neurotransmitter mechanisms.
Tony Booley, Director – International BSc Physiology, MBA, Chartered Marketer; 30yrs sector experience, with Alliance since 1998
29 29
Product portfolio BRAND NON-PROPRIETARY NAME USES
Acnisal 2% salicylic acid A medicated cleanser for the treatment and prevention of acne
Actidose-Aqua* activated charcoal An activated charcoal suspension for the emergency treatment of acute poisoning and drug overdose for a number of substances
Alphaderm hydrocortisone and urea An anti-inflammatory and hydrating cream used in the treatment of inflammatory dermatoses such as eczema and psoriasis
Anbesol Adult Strength Gel
lidocaine hydrochloride 2% chlorocresol 0.1% cetylpyridinium chloride 0.02%
For the temporary relief of pain caused by recurrent mouth ulcers and denture irritation
Anbesol Liquid lidocaine hydrochloride 0.9% chlorocresol 0.1% cetylpyridinium chloride 0.02%
For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething
Anbesol Teething Gel lidocaine hydrochloride 1% chlorocresol 0.1% cetylpyridinium chloride 0.02%
For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething
Ashton and Parsons tincture of matricaria This is a herbal product traditionally used in infants for the symptomatic relief of pain and gastric upset associated with teething
Aquadrate 10% urea A hydrating cream used in the treatment of dry, scaling and itchy skin disorders.
Including: ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions
Atarax hydroxyzine hydrochloride For pruritus (itching) associated with acute and chronic urticaria in children and adults. Also for anxiety in adults
Buccastem & Buccastem M
prochlorperazine maleate A prescription treatment for nausea and vomiting, and for symptomatic treatment of other conditions such as vertigo. As an OTC product Buccastem M is used by migraine sufferers. It comes in a special buccal tablet formulation which adheres to the gum and releases the drug over one to two hours. This has a particular advantage as vomiting patients may encounter difficulties taking tablets orally
Cafergot* ergotamine tartrate and caffeine For the management of acute attacks of migraine headache in patients who have
not responded to simple analgesics
30 30
Product portfolio BRAND NON-PROPRIETARY NAME USES
Calcium Sandoz* calcium glubionate and calcium lactobionate
A calcium supplement used to maintain calcium levels. It is given in neonatal hypocalcaemia. It may help to replace lost calcium and reduce the risk of broken bones in elderly patients with osteoporosis.
Ceanel Concentrate
cetrimide undecenoic Acid
A clear, viscous, golden-yellow coloured liquid, used as an adjunct in the management psoriasis of the scalp, seborrhoeic dermatitis, dandruff-psoriasis of the trunk and limbs.
Deltacortril prednisolone Gastro-resistant tablets. Used for a wide range of disorders in which systemic
corticosteroids are indicated, including allergies, arteritis, rheumatic fever, rheumatic disorders, autoimmune disorders etc
Dermamist white soft paraffin Treatment of dry skin conditions including eczema, ichthyosis and pruritus in the elderly
Deseril*
methysergide Used for the prevention of migraine in patients who have not responded to alternative therapies. It is also used in the management of diarrhoea associated with carcinoid disease.
Dicobalt Edetate
dicobalt edetate Dicobalt injection is a specific antidote for acute cyanide poisoning. In view of the difficulty of certain diagnosis in emergency situations, it is recommended that Dicobalt Edetate only be given when the patient is tending to lose or has lost consciousness.
Distamine
penicillamine A disease modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (not osteoarthritis), Wilson's disease (toxic accumulation of copper), lead poisoning and cystinuria (formation of cystine stones in the kidneys).
Edrophonium* edrophonium chloride Myasthenia gravis, as a diagnostic test; to distinguish between overdosage and
underdosage of cholinergic drugs in myasthenic patients; diagnosis of suspected ‘dual block’; antagonist to non-depolarising neuromuscular blockade.
Forceval
multivitamin and mineral preparation
Capsules containing 24 essential vitamins and minerals (22 in the Junior capsules). Available on prescription unlike other preparations for use in patients with nutritional deficits due to disease e.g. AIDS, cancer, inflammatory bowel disease, or on restricted diets e.g. food intolerances, galactosaemia.
31 31
Product portfolio BRAND NON-PROPRIETARY NAME USES
Gelclair*
polyvinylpyrrolidone A viscous gel specially formulated to aid the management of lesions of the oral mucosa. It forms a protective film that, by adhering to the mucosa of the oropharyngeal cavity, can prevent further irritations thus contributing to the rapid relief of pain.
Hydromol Cream sodium pyrrolidone carboxylate 2.5% Cream for the treatment of dry skin conditions including dermatitis, eczema, ichthyosis and senile pruritus
Hydromol Bath & Shower Emollient
light liquid paraffin (37.8%) and isopropyl myristate (13%)
For the treatment of dry skin conditions such as eczema, ichthyosis and senile pruritus
Hydromol Ointment Yellow soft paraffin (30%) and emulsifying wax (30%)
Ointment for moisturizing and softening dry skin. May be used as a soap substitute
Hydromol Intensive 10% urea A hydrating cream used in the treatment of dry, scaling and itchy skin disorders.
Including: ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions
Hydromol HC Intensive
hydrocortisone and urea An anti-inflammatory and hydrating cream used in the treatment of inflammatory dermatoses such as eczema and psoriasis.
Hygroton chlortalidone A diuretic to treat mild to moderate hypertension and oedema. Also used for diabetes insipidus (excessive urination).
Immucyst*
bacillus of calmette and guérin Indicated for intra-vesicular use in the treatment and prophylaxis of primary or recurrent carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis following transurethral resection (TUR) of primary or recurrent stage Ta and/or T1 papillary tumours, or any combination thereof, regardless of antecedent intra-vesicular treatment.
Isocarboxazid* isocarboxazid For the treatment of the symptoms of depressive illness. (monoamine oxidase inhibitor)
Isoniazid* isoniazid
For all forms of pulmonary and extra-pulmonary tuberculosis.
Isotretinoin isotretinoin
For the treatment of severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring), resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy
32 32
Product portfolio BRAND NON-PROPRIETARY NAME USES
Lysovir amantadine Used for the prevention and treatment of influenza A
Menadiol* menadiol diphospate (as menadiol sodium diphospate)
For the treatment of haemorrhage associated with a low blood level of prothrombin or factor vii. The main indication is obstructive jaundice (before and after surgery)
Meted 3% salicylic acid & 5% sulphur A medicated shampoo for the treatment of seborrhoeic dermatitis, scalp dermatitis and dandruff. Relieves the itching, irritation, erythema and flaking
Metopirone*
Metyrapone Used in the diagnosis of certain problems of the adrenal glands. It is also used for the management of Cushing's syndrome (a rare disorder, mainly of females, characterized by a moonface, obesity and excessive growth of hair) and oedema.
Molipaint potassium hydrochloride For the treatment of molluscum contagiosum
Naseptin chlorhexidine neomycin An antimicrobial cream for inside the nose. It is used for eradicating staphylococcus infections in the nose.
Neostigmine Bromide
neostigmine bromide Myasthenia gravis; paralytic ileus; post-operative urinary retention. Neostigmine Bromide Tablets are used mainly for the treatment of myasthenia gravis, a disease in which the muscles are weak and tire easily. They are also used when the normal movements of the intestine are absent and for the treatment of urinary retention after surgery.
Nu-Seals
aspirin, gastro-resistant tablets Low and standard dose aspirin with a protective coat to protect against GI side effects of aspirin. Low dose is used to prevent heart attacks and ischaemic strokes in patients with risk factors. Standard dose used for all aspirin indications except acute pain relief.
Occlusal 26% salicylic acid A topical solution for the treatment and prevention of common and planar warts.
Ondemet ondansetron hydrochloride dehydrate
For the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention of post-operative nausea and vomiting (PONV).
Oxymetholone* oxymetholone Oral tablet formulation synthetic male homone, which enhances and repairs the
body tissue-building process as a treatment for aplastic and refractory anaemias
33 33
Product portfolio BRAND NON-PROPRIETARY NAME USES
Pavacol-D pholcodine A sugar free liquid for the symptomatic treatment of dry troublesome coughs.
Pentagastrin* pentagastrin Pentagastrin Injection BP is used for the diagnostic testing of gastric secretion.
Pentrax fractar 5 coal tar extract A shampoo for the treatment of seborrhoeic dermatitis, scalp dermatitis and
dandruff. Relieves the itching, irritation, erythema, flaking and scaling
Periostat doxycycline Subantimicrobial dose doxycycline used for the treatment of periodontitis. By
suppressing tissue destructive MMP enzymes, it has an anti-inflammatory rather than an antimicrobial action. Licensed in Europe through MRP
Permitabs potassium permanganate A mild antiseptic, used to clean and deodorise oozing, eczematous skin conditions and wounds
Phenytoin
phenytoin sodium For the control of status epilepticus of the tonic-clonic (grand mal type) and the prevention and treatment of seizures occurring during or following neurosurgery and/or severe head injury. Also used in the treatment of cardiac arrhythmias where first line therapy is not effective. It is of particular value when these are digitalis induced.
Procarbazine Capsules
procarbazine hydrochloride The main indication is Hodgkin's disease (lymphadenoma). Procarbazine may also be useful in other advanced lymphomata and a variety of solid tumours which have proved resistant to other forms of therapy.
Quinoderm Cream benzyl peroxide potassium hydroxyquinoline sulphate
A creamy white astringent vanishing cream for acne vulgaris, acne form eruptions and folliculitis.
Quinoderm Antibacterial Facewash
chlorhexidine gluconate cetrimide An antimicrobial soap substitute, designed to kill harmful bacteria found on the skin, to be used both morning and night.
Ranitidine
ranitidine hydrochloride For the treatment of duodenal ulcer, benign gastric ulcer, post-operative ulcer and of Zollinger-Ellison Syndrome. For the managements of conditions where reduction of gastric secretion and acid output is desirable, such as reflux oesphagitis. As prophylaxis against gastrointestinal haemorrhage from stress ulceration, recurrent haemorrhage and acid aspitaion (Medelson's Syndrome) before anaesthesia.
34 34
Product portfolio BRAND NON-PROPRIETARY NAME USES
Rogitine*
phentolamine Used in the diagnosis of phaeochromocytoma, a tumour of the adrenal gland and in the management of hypertensive episodes associated with phaeochromocytoma.
Sinthrome*
acenocoumarol An oral anticoagulant used in the treatment or prevention of thromboembolic disorders.
Slow-K*
potassium chloride A potassium supplement used to correct low potassium levels associated with disease, poor diet or other drug therapy.
Symmetrel*
amantadine Used in the treatment of Parkinson's disease and herpes zoster but only in those patients who you could expect to get a severe and painful rash. The syrup is also useful in the treatment and prevention of influenza type A.
Synacthen* tetracosactide Used in the diagnosis of adrenocortical insufficiency. Stimulates the formation of adrenal steroids (cortisol).
Synacthen Depot* tetracosactide – slow release A long acting formulation of Synacthen. In addition, it is used to treat various
inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and osteoarthritis in short term use only.
Syntocinon*
oxytocin A synthetic form of the hormone oxytocin, used in the induction of labour, the management of missed and incomplete abortion and to stop excessive bleeding following delivery.
Syntometrine*
ergometrine maleate oxytocin A combination of oxytocin and ergometrine used during the last stage of childbirth of following delivery of the placenta to prevent or beat postpartum haemorrhage
Testosterone Enantate*
testosterone enantate Used for the treatment of andropause - males who have too little or no endogenous testosterone production.
Timodine
nystatin, 100,000 IU/g 3% w/w dimeticone 350 10%, hydrocortisone 0.5%w/w benzalkonium chloride solution 0.2% w/w
Anti-fungal and anti-bacterial skin cream used for treating inflamed and infected skin conditions in which the Candida albicans fungus is a factor. Uses include treatment of severe nappy rash, eczema and other dermatoses
35 35
Product portfolio
BRAND NON-PROPRIETARY NAME USES
Uniflu with Gregovite C*
caffeine, codeine, diphenhydramine, paracetamol, phenylephrine, vitamin C
Uniflu tablets and Gregovite C tablets. For the relief from the signs and symptoms of colds and flue
Valaciclovir
valaciclovir hydrochloride For the treatment of shingles (herpes zoster) infaction, the treatment and prophylaxis of herpes simplex infections of the skin and mucous membranes, including genital herpes. For the prophylaxis of cytomegalovirus (CMV) infection following renal transplantion
Vitamin E Suspension*
vitamin E suspension Vitamin E deficiency in malabsorption disorders. It is the only UK licensed liquid formulation treatment for the correction of Vitamin E malabsorption in conditions such as including Cystic Fibrosis (CF, primary indication) and chronic cholestasis. The active ingredient is tocopherol acetate, a synthetic form of vitamin E.
Xenazine*
tetrabenazine
Xenazine IR is used for alleviation of a wide range of hyperkinetic movement disorders such as chorea associated with Huntington’s disease (HD); tardive dyskinesias and tics associated with Tourettes syndrome. Tetrabenazine interferes with the normal action of dopamine to dampen neuro-transmission along motor pathways.
List contains licensed products * Brand names appearing throughout this report are trademarks either owned by and/or licensed to Alliance Pharmaceuticals Limited, with the exception of Actidose-Aqua, trademark of Paddock Labs Inc, Cafergot, Calcium Sandoz, Deseril, Hygroton, Metopirone, Rogitine, Slow-K, Synacthen, Synacthen Depot, Syntocinon, Syntometrine, trademarks of Novartis AG, Symmetrel, trademark of Endo Pharmacetucials Inc and Gregovite C, trademark of G R Lane, Gelclair trademark of Helsinn, ImmuCyst trademark of Sanofi Pasteur, Xenazine trademark of Biovail.